CG Bio said it has signed contracts to export 5.7 billion won ($4.4 million) worth of Facetem S and AiLEENE, its filler products, to the Middle East and Sweden.

The company will export 4.9 billion won worth of its HA fillers to seven Middle East countries, including Syria and the Gulf Cooperation Organization (GCC) member states of Saudi Arabia and UAE, and 800 million won worth to Sweden.

CG Bio said it could conclude the deal with Sweden at the recent International Aesthetic Plastic Surgery Society (IMCAS) 2022 in Paris from June 3-5. CG Bio had operated a PR booth at the convention and actively promoted the excellence of filler products, and was able to hold business meetings with about 150 companies.

“IMCAS 2022 was an event to promote the excellent technology of CG Bio Filler products and get a sense of buyers' interest worldwide,” CG Bio CEO Yu Hyun-seung said. “We will continue to expand the global market by discovering new buyers by developing innovative medical devices and attending overseas conferences.”

Facetem S is calcium filler manufactured with a lattice-pore structure, in which high-purity 99.49 percent hydroxyapatite (HA) particles processed with CG Bio’s manufacturing technology are stacked with hard shells. The characteristic of the filler includes preventing sudden volume decrease and enhancing the feeling of injection with uniform particles.

The company exports Facetem S after obtaining local licenses in eight countries, including Russia and Spain.

AiLEENE is a hyaluronic acid filler applying the world's first two-in-one multi-layered phasic method that mixes cross-linked gel and cross-linked particles with a patented method and then applies a rotation process. The filler also improves safety by minimizing the modification of degree value. However, according to CG Bio, this factor can cause side effects such as edema and inflammation while filling well with high volume and cohesiveness.